Indirect Comparison of Lanadelumab and Intravenous C1-INH Using Data from the HELP and CHANGE Studies: Bayesian and Frequentist Analyses
Author:
Funder
Takeda Pharmaceutical Company
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology
Link
http://link.springer.com/content/pdf/10.1007/s40268-021-00337-4.pdf
Reference29 articles.
1. Maurer M, Magerl M, Ansotegui I, Aygören-Pürsün E, Betschel S, Bork K, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—the 2017 revision and update. Allergy. 2018;73(8):1575–96. https://doi.org/10.1111/all.13384.
2. Lang DM, Aberer W, Bernstein JA, Chng HH, Grumach AS, Hide M, et al. International consensus on hereditary and acquired angioedema. Ann Allergy Asthma Immunol. 2012;109(6):395–402. https://doi.org/10.1016/j.anai.2012.10.008.
3. Zuraw BL, Banerji A, Bernstein JA, Busse PJ, Christiansen SC, Davis-Lorton M, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract. 2013;1(5):458–67. https://doi.org/10.1016/j.jaip.2013.07.002.
4. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119(3):267–74. https://doi.org/10.1016/j.amjmed.2005.09.064.
5. Banerji A, Davis KH, Brown TM, Hollis K, Hunter SM, Long J, et al. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States. Ann Allergy Asthma Immunol. 2020;124(6):600–7. https://doi.org/10.1016/j.anai.2020.02.018 ((Epub ahead of print)).
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Patient‐level indirect treatment comparison of lanadelumab versus pdC1‐INH i.v. in hereditary angioedema patients: PATCH study;Allergy;2023-08-29
2. Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema;Journal of Comparative Effectiveness Research;2023-06
3. Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada;Allergy, Asthma & Clinical Immunology;2021-07-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3